{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:10:09Z","timestamp":1792696209887,"version":"4.5.0"},"reference-count":147,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2017,7,14]],"date-time":"2017-07-14T00:00:00Z","timestamp":1499990400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1038\/nrneurol.2017.84","type":"journal-article","created":{"date-parts":[[2017,7,14]],"date-time":"2017-07-14T14:13:25Z","timestamp":1500041605000},"page":"533-547","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":215,"title":["Autoantibodies in chronic inflammatory neuropathies: diagnostic and therapeutic implications"],"prefix":"10.1038","volume":"13","author":[{"given":"Luis","family":"Querol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Devaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricard","family":"Rojas-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Illa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,14]]},"reference":[{"key":"BFnrneurol201784_CR1","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/nrneurol.2014.117","volume":"10","author":"N Latov","year":"2014","unstructured":"Latov, N. Diagnosis and treatment of chronic acquired demyelinating polyneuropathies. Nat. Rev. Neurol. 10, 435\u2013446 (2014).","journal-title":"Nat. Rev. Neurol."},{"key":"BFnrneurol201784_CR2","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/jns5.12053","volume":"19","author":"E Nobile-Orazio","year":"2014","unstructured":"Nobile-Orazio, E. 2013 Peripheral Nerve Society Meeting PNS Presidential Lecture. Chronic inflammatory demyelinating polyradiculoneuropathy and variants: where we are and where we should go. J. Peripher. Nerv. Syst. 19, 2\u201313 (2014).","journal-title":"J. Peripher. Nerv. Syst."},{"key":"BFnrneurol201784_CR3","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/j.1468-1331.2009.02930.x","volume":"17","author":"PY Van den Bergh","year":"2010","unstructured":"Van den Bergh, P. Y.  et al. European Federation of Neurological Societies\/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur. J. Neurol. 17, 356\u2013363 (2010).","journal-title":"Eur. J. Neurol."},{"key":"BFnrneurol201784_CR4","unstructured":"Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies\/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society \u2014 first revision. J. Peripher. Nerv. Syst. 15, 295\u2013301 (2010)."},{"key":"BFnrneurol201784_CR5","unstructured":"Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies\/Peripheral Nerve Society guideline on management of paraproteinemic demyelinating neuropathies. Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society \u2014 first revision. J. Peripher. Nerv. Syst. 15, 185\u2013195 (2010)."},{"key":"BFnrneurol201784_CR6","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1016\/j.jdiacomp.2016.05.007","volume":"30","author":"V Bril","year":"2016","unstructured":"Bril, V.  et al. The dilemma of diabetes in chronic inflammatory demyelinating polyneuropathy. J. Diabetes Complications 30, 1401\u20131407 (2016).","journal-title":"J. Diabetes Complications"},{"key":"BFnrneurol201784_CR7","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/j.1529-8027.2010.00251.x","volume":"15","author":"K Viala","year":"2010","unstructured":"Viala, K.  et al. A current view of the diagnosis, clinical variants, response to treatment and prognosis of chronic inflammatory demyelinating polyradiculoneuropathy. J. Peripher. Nerv. Syst. 15, 50\u201356 (2010).","journal-title":"J. Peripher. Nerv. Syst."},{"key":"BFnrneurol201784_CR8","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1212\/WNL.0000000000001833","volume":"85","author":"JA Allen","year":"2015","unstructured":"Allen, J. A. & Lewis, R. A. CIDP diagnostic pitfalls and perception of treatment benefit. Neurology 85, 498\u2013504 (2015).","journal-title":"Neurology"},{"key":"BFnrneurol201784_CR9","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1136\/jnnp-2014-309697","volume":"86","author":"EK Mathey","year":"2015","unstructured":"Mathey, E. K.  et al. Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype. J. Neurol. Neurosurg. Psychiatry 86, 973\u2013985 (2015).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"Suppl. 1","key":"BFnrneurol201784_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1529-8027.2011.00298.x","volume":"16","author":"TH Brannagan","year":"2011","unstructured":"Brannagan, T. H. Current diagnosis of CIDP: the need for biomarkers. J. Peripher. Nerv. Syst. 16 (Suppl. 1), 3\u201313 (2011).","journal-title":"J. Peripher. Nerv. Syst."},{"key":"BFnrneurol201784_CR11","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/nrneurol.2011.175","volume":"8","author":"L Vlam","year":"2012","unstructured":"Vlam, L.  et al. Multifocal motor neuropathy: diagnosis, pathogenesis and treatment strategies. Nat. Rev. Neurol. 8, 48\u201358 (2012).","journal-title":"Nat. Rev. Neurol."},{"key":"BFnrneurol201784_CR12","doi-asserted-by":"publisher","first-page":"e225","DOI":"10.1016\/j.lpm.2013.02.329","volume":"42","author":"R Rojas-Garc\u00eda","year":"2013","unstructured":"Rojas-Garc\u00eda, R., Gallardo, E. & Illa, I. Paraproteinemic neuropathies. Presse Med. 42, e225\u2013e234 (2013).","journal-title":"Presse Med."},{"key":"BFnrneurol201784_CR13","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/ncpneuro0452","volume":"3","author":"G Meyer zu H\u00f6rste","year":"2007","unstructured":"Meyer zu H\u00f6rste, G., Hartung, H.-P. & Kieseier, B. C. From bench to bedside \u2014 experimental rationale for immune-specific therapies in the inflamed peripheral nerve. Nat. Clin. Pract. Neurol. 3, 198\u2013211 (2007).","journal-title":"Nat. Clin. Pract. Neurol."},{"key":"BFnrneurol201784_CR14","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.neurol.2014.07.006","volume":"170","author":"J-M Vallat","year":"2014","unstructured":"Vallat, J.-M. Peripheral nervous system neuroimmunology seen by a neuro-pathologist. Rev. Neurol. (Paris) 170, 564\u2013569 (2014).","journal-title":"Rev. Neurol. (Paris)"},{"key":"BFnrneurol201784_CR15","first-page":"1","volume":"74","author":"K Shibuya","year":"2014","unstructured":"Shibuya, K.  et al. Reconstruction magnetic resonance neurography in chronic inflammatory demyelinating polyneuropathy. Ann. Neurol. 74, 1\u20135 (2014).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol201784_CR16","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/mus.25368","volume":"55","author":"T Ishikawa","year":"2016","unstructured":"Ishikawa, T.  et al. MR neurography for the evaluation of CIDP. Muscle Nerve 55, 483\u2013489 (2016).","journal-title":"Muscle Nerve"},{"key":"BFnrneurol201784_CR17","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/S1474-4422(07)70329-0","volume":"7","author":"RA Hughes","year":"2008","unstructured":"Hughes, R. A.  et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol. 7, 136\u2013144 (2008).","journal-title":"Lancet Neurol."},{"key":"BFnrneurol201784_CR18","first-page":"CD003906","volume":"8","author":"MM Mehndiratta","year":"2015","unstructured":"Mehndiratta, M. M., Hughes, R. A. & Pritchard, J. Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst. Rev. 8, CD003906 (2015).","journal-title":"Cochrane Database Syst. Rev."},{"key":"BFnrneurol201784_CR19","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/jns5.12048","volume":"296","author":"M Berger","year":"2013","unstructured":"Berger, M., McCallus, D. E. & Lin, C. S.-Y. Rapid and reversible responses to IVIg in autoimmune neuromuscular diseases suggest mechanisms of action involving competition with functionally important autoantibodies. J. Peripher. Nerv. Syst. 296, 275\u2013296 (2013).","journal-title":"J. Peripher. Nerv. Syst."},{"key":"BFnrneurol201784_CR20","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s11940-010-0065-x","volume":"12","author":"MC Dalakas","year":"2010","unstructured":"Dalakas, M. C. Pathogenesis and treatment of anti-MAG neuropathy. Curr. Treat. Opt. Neurol. 12, 71\u201383 (2010).","journal-title":"Curr. Treat. Opt. Neurol."},{"key":"BFnrneurol201784_CR21","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1093\/brain\/124.10.1968","volume":"124","author":"HJ Willison","year":"2001","unstructured":"Willison, H. J.  et al. The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies. Brain 124, 1968\u20131977 (2001).","journal-title":"Brain"},{"key":"BFnrneurol201784_CR22","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/ana.410240113","volume":"24","author":"A Pestronk","year":"1988","unstructured":"Pestronk, A.  et al. A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Ann. Neurol. 24, 73\u201378 (1988).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol201784_CR23","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1212\/WNL.0b013e3181ff94c2","volume":"75","author":"EA Cats","year":"2010","unstructured":"Cats, E. A.  et al. Multifocal motor neuropathy: association of anti-GM1 IgM antibodies with clinical features. Neurology 75, 1961\u20131967 (2010).","journal-title":"Neurology"},{"key":"BFnrneurol201784_CR24","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1002\/ana.23794","volume":"73","author":"L Querol","year":"2013","unstructured":"Querol, L.  et al. Antibodies to contactin-1 in chronic inflammatory demyelinating polyneuropathy. Ann. Neurol. 73, 370\u2013380 (2013).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol201784_CR25","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1212\/WNL.0000000000000205","volume":"82","author":"L Querol","year":"2014","unstructured":"Querol, L.  et al. Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg. Neurology 82, 879\u2013886 (2014).","journal-title":"Neurology"},{"key":"BFnrneurol201784_CR26","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1093\/brain\/aww189","volume":"139","author":"K Doppler","year":"2016","unstructured":"Doppler, K.  et al. Auto-antibodies to contactin-associated protein 1 (Caspr) in two patients with painful inflammatory neuropathy. Brain 139, 2617\u20132630 (2016).","journal-title":"Brain"},{"key":"BFnrneurol201784_CR27","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/j.1471-1842.2009.00848.x","volume":"26","author":"MJ Grant","year":"2009","unstructured":"Grant, M. J. & Booth, A. A typology of reviews: an analysis of 14 review types and associated methodologies. Health Info. Libr. J. 26, 91\u2013108 (2009).","journal-title":"Health Info. Libr. J."},{"key":"BFnrneurol201784_CR28","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1212\/WNL.33.2.234","volume":"33","author":"B Zweiman","year":"1983","unstructured":"Zweiman, B., Rostami, A., Lisak, R. P., Moskovitz, A. R. & Pleasure, D. E. Immune reactions to P2 protein in human inflammatory demyelinative neuropathies. Neurology 33, 234\u2013237 (1983).","journal-title":"Neurology"},{"key":"BFnrneurol201784_CR29","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.autrev.2014.08.005","volume":"13","author":"LJ Pei","year":"2014","unstructured":"Pei, L. J., Devaux, J. & Yuki, N. Peripheral nerve proteins as potential autoantigens in acute and chronic inflammatory demyelinating polyneuropathies. Autoimmun. Rev. 13, 1070\u20131078 (2014).","journal-title":"Autoimmun. Rev."},{"key":"BFnrneurol201784_CR30","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1001\/archneur.1980.00500590061010","volume":"37","author":"MC Dalakas","year":"1980","unstructured":"Dalakas, M. C. & Engel, W. K. Immunoglobulin and complement deposits in nerves of patients with chronic relapsing polyneuropathy. Arch. Neurol. 37, 637\u2013640 (1980).","journal-title":"Arch. Neurol."},{"key":"BFnrneurol201784_CR31","doi-asserted-by":"publisher","first-page":"4788","DOI":"10.1073\/pnas.0807319106","volume":"106","author":"B Tackenberg","year":"2009","unstructured":"Tackenberg, B.  et al. Impaired inhibitory Fc\u03b3 receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy. Proc. Natl Acad. Sci. USA 106, 4788\u20134792 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneurol201784_CR32","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/1531-8249(200006)47:6<765::AID-ANA9>3.0.CO;2-8","volume":"47","author":"WX Yan","year":"2000","unstructured":"Yan, W. X., Taylor, J., Andrias-Kauba, S. & Pollard, J. D. Passive transfer of demyelination by serum or IgG from chronic inflammatory demyelinating polyneuropathy patients. Ann. Neurol. 47, 765\u2013775 (2000).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol201784_CR33","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/j.1529-8027.2012.00372.x","volume":"17","author":"JJ Devaux","year":"2012","unstructured":"Devaux, J. J., Odaka, M. & Yuki, N. Nodal proteins are target antigens in Guillain\u2013Barr\u00e9 syndrome. J. Peripher. Nerv. Syst. 17, 62\u201371 (2012).","journal-title":"J. Peripher. Nerv. Syst."},{"key":"BFnrneurol201784_CR34","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1097\/WCO.0000000000000233","volume":"28","author":"L Querol","year":"2015","unstructured":"Querol, L. & Illa, I. Paranodal and other autoantibodies in chronic inflammatory neuropathies. Curr. Opin. Neurol. 28, 474\u2013479 (2015).","journal-title":"Curr. Opin. Neurol."},{"key":"BFnrneurol201784_CR35","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1113\/jphysiol.1949.sp004335","volume":"108","author":"AF Huxley","year":"1949","unstructured":"Huxley, A. F. & St\u00e4mpeli, R. Evidence for saltatory conduction in peripheral myelinated nerve fibres. J. Physiol. 108, 315\u2013339 (1949).","journal-title":"J. Physiol."},{"key":"BFnrneurol201784_CR36","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1007\/BF00323315","volume":"64","author":"W Bargmann","year":"1964","unstructured":"Bargmann, W. & Lindner, E. On the fine structure of the adrenal medulla of the hedgehog (Erinaceus europaeus L.) [German]. Z. Zellforsch. Mikrosk. Anat. 64, 868\u2013912 (1964).","journal-title":"Z. Zellforsch. Mikrosk. Anat."},{"key":"BFnrneurol201784_CR37","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0896-6273(01)00296-3","volume":"30","author":"ME Boyle","year":"2001","unstructured":"Boyle, M. E.  et al. Contactin orchestrates assembly of the septate-like junctions at the paranode in myelinated peripheral nerve. Neuron 30, 385\u2013397 (2001).","journal-title":"Neuron"},{"key":"BFnrneurol201784_CR38","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S0960-9822(01)00680-7","volume":"12","author":"P Charles","year":"2002","unstructured":"Charles, P.  et al. Neurofascin is a glial receptor for the paranodin\/Caspr-contactin axonal complex at the axoglial junction. Curr. Biol. 12, 217\u2013220 (2002).","journal-title":"Curr. Biol."},{"key":"BFnrneurol201784_CR39","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1002\/jnr.22015","volume":"87","author":"AM Pillai","year":"2009","unstructured":"Pillai, A. M.  et al. Spatiotemporal ablation of myelinating glia-specific neurofascin (Nfasc NF155) in mice reveals gradual loss of paranodal axoglial junctions and concomitant disorganization of axonal domains. J. Neurosci. Res. 87, 1773\u20131793 (2009).","journal-title":"J. Neurosci. Res."},{"key":"BFnrneurol201784_CR40","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S0896-6273(01)00294-X","volume":"30","author":"M Bhat","year":"2001","unstructured":"Bhat, M. a  et al. Axon\u2013glia interactions and the domain organization of myelinated axons requires neurexin IV\/Caspr\/Paranodin. Neuron 30, 369\u2013383 (2001).","journal-title":"Neuron"},{"key":"BFnrneurol201784_CR41","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nrneurol.2014.260","volume":"11","author":"P Stathopoulos","year":"2015","unstructured":"Stathopoulos, P., Alexopoulos, H. & Dalakas, M. C. Autoimmune antigenic targets at the node of Ranvier in demyelinating disorders. Nat. Rev. Neurol. 11, 143\u2013156 (2015).","journal-title":"Nat. Rev. Neurol."},{"key":"BFnrneurol201784_CR42","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/ana.410400414","volume":"40","author":"C Hafer-Macko","year":"1996","unstructured":"Hafer-Macko, C.  et al. Acute motor axonal neuropathy: an antibody-mediated attack on axolemma. Ann. Neurol. 40, 635\u2013644 (1996).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol201784_CR43","doi-asserted-by":"publisher","first-page":"e14533","DOI":"10.1371\/journal.pone.0014533","volume":"6","author":"C Cifuentes-Diaz","year":"2011","unstructured":"Cifuentes-Diaz, C.  et al. Nodes of Ranvier and paranodes in chronic acquired neuropathies. PLoS ONE 6, e14533 (2011).","journal-title":"PLoS ONE"},{"key":"BFnrneurol201784_CR44","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/jns5.12023","volume":"18","author":"K Doppler","year":"2013","unstructured":"Doppler, K., Werner, C. & Sommer, C. Disruption of nodal architecture in skin biopsies of patients with demyelinating neuropathies. J. Peripher. Nerv. Syst. 18, 168\u2013176 (2013).","journal-title":"J. Peripher. Nerv. Syst."},{"key":"BFnrneurol201784_CR45","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1093\/brain\/awn281","volume":"132","author":"A Lonigro","year":"2009","unstructured":"Lonigro, A. & Devaux, J. J. Disruption of neurofascin and gliomedin at nodes of Ranvier precedes demyelination in experimental allergic neuritis. Brain 132, 260\u2013273 (2009).","journal-title":"Brain"},{"key":"BFnrneurol201784_CR46","first-page":"288","volume":"15","author":"WX Yan","year":"2010","unstructured":"Yan, W. X., Mathey, E., Yiannikas, C. & Pollard, J. Antineurofascin antibodies are present in patients with peripheral demyelinating neuropathies and mediate changes in nerve conduction in animals. J. Peripher. Nerv. Syst. 15, 288\u2013289 (2010).","journal-title":"J. Peripher. Nerv. Syst."},{"key":"BFnrneurol201784_CR47","doi-asserted-by":"publisher","first-page":"e173","DOI":"10.1093\/brain\/awq372","volume":"134","author":"H Pr\u00fcss","year":"2011","unstructured":"Pr\u00fcss, H., Schwab, J. M., Derst, C., G\u00f6rtzen, A. & Veh, R. W. Neurofascin as target of autoantibodies in Guillain\u2013Barr\u00e9 syndrome. Brain 134, e173 (2011).","journal-title":"Brain"},{"key":"BFnrneurol201784_CR48","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1136\/jnnp-2014-310097","volume":"86","author":"A Uncini","year":"2015","unstructured":"Uncini, A. & Kuwabara, S. Nodopathies of the peripheral nerve: an emerging concept. J. Neurol. Neurosurg. Psychiatry 86, 1186\u20131195 (2015).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BFnrneurol201784_CR49","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1016\/j.clinph.2013.03.025","volume":"124","author":"A Uncini","year":"2013","unstructured":"Uncini, A., Susuki, K. & Yuki, N. Nodo-paranodopathy: beyond the demyelinating and axonal classification in anti-ganglioside antibody-mediated neuropathies. Clin. Neurophysiol. 124, 1928\u20131934 (2013).","journal-title":"Clin. Neurophysiol."},{"key":"BFnrneurol201784_CR50","doi-asserted-by":"publisher","first-page":"7907","DOI":"10.1074\/jbc.M113.528489","volume":"289","author":"M Labasque","year":"2014","unstructured":"Labasque, M.  et al. Specific contactin N-glycans are implicated in neurofascin binding and autoimmune targeting in peripheral neuropathies. J. Biol. Chem. 289, 7907\u20137918 (2014).","journal-title":"J. Biol. Chem."},{"issue":"Suppl. 1","key":"BFnrneurol201784_CR51","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.1007\/s10875-010-9398-1","volume":"30","author":"B Tackenberg","year":"2010","unstructured":"Tackenberg, B., Nimmerjahn, F. & L\u00fcnemann, J. D. Mechanisms of IVIg efficacy in chronic inflammatory demyelinating polyneuropathy. J. Clin. Immunol. 30 (Suppl. 1), S65\u2013S69 (2010).","journal-title":"J. Clin. Immunol."},{"key":"BFnrneurol201784_CR52","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1093\/brain\/awv054","volume":"138","author":"Y Miura","year":"2015","unstructured":"Miura, Y.  et al. Contactin 1 IgG4 associates to chronic inflammatory demyelinating polyneuropathy with sensory ataxia. Brain 138, 1484\u20131491 (2015).","journal-title":"Brain"},{"key":"BFnrneurol201784_CR53","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1136\/jnnp-2014-309916","volume":"86","author":"K Doppler","year":"2015","unstructured":"Doppler, K.  et al. Destruction of paranodal architecture in inflammatory neuropathy with anti-contactin-1 autoantibodies. J. Neurol. Neurosurg. Psychiatry 86, 720\u2013728 (2015).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BFnrneurol201784_CR54","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1111\/ene.12758","volume":"22","author":"MG Huijbers","year":"2015","unstructured":"Huijbers, M. G.  et al. The expanding field of IgG4-mediated neurological autoimmune disorders. Eur. J. Neurol. 22, 1151\u20131161 (2015).","journal-title":"Eur. J. Neurol."},{"key":"BFnrneurol201784_CR55","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1093\/brain\/aww062","volume":"139","author":"C Manso","year":"2016","unstructured":"Manso, C., Querol, L., Mekaouche, M., Illa, I. & Devaux, J. J. Contactin-1 IgG4 antibodies cause paranode dismantling and conduction defects. Brain 139, 1700\u20131712 (2016).","journal-title":"Brain"},{"key":"BFnrneurol201784_CR56","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1136\/jnnp-2016-314895","volume":"88","author":"H Koike","year":"2017","unstructured":"Koike, H.  et al. Paranodal dissection in chronic inflammatory demyelinating polyneuropathy with antineurofascin-155 and anticontactin-1 antibodies. J. Neurol. Neurosurg. Psychiatry 88, 465\u2013473 (2017).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BFnrneurol201784_CR57","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1212\/WNL.0b013e31827689ad","volume":"79","author":"JK Man","year":"2012","unstructured":"Man, J. K.  et al. Neurofascin as a target for autoantibodies in peripheral neuropathies. Neurology 79, 2241\u20132248 (2012).","journal-title":"Neurology"},{"key":"BFnrneurol201784_CR58","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1212\/WNL.0000000000002418","volume":"86","author":"JJ Devaux","year":"2016","unstructured":"Devaux, J. J.  et al. Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy. Neurology 86, 800\u2013807 (2016).","journal-title":"Neurology"},{"key":"BFnrneurol201784_CR59","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1002\/acn3.248","volume":"2","author":"H Ogata","year":"2015","unstructured":"Ogata, H.  et al. Characterization of IgG4 anti-neurofascin 155 antibody-positive polyneuropathy. Ann. Clin. Transl. Neurol. 2, 960\u2013971 (2015).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"BFnrneurol201784_CR60","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jneuroim.2016.10.013","volume":"301","author":"M Kadoya","year":"2016","unstructured":"Kadoya, M.  et al. IgG4 anti-neurofascin155 antibodies in chronic inflammatory demyelinating polyradiculoneuropathy: clinical significance and diagnostic utility of a conventional assay. J. Neuroimmunol. 301, 16\u201322 (2016).","journal-title":"J. Neuroimmunol."},{"key":"BFnrneurol201784_CR61","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1212\/WNL.0b013e3182a1aa9c","volume":"81","author":"N Kawamura","year":"2013","unstructured":"Kawamura, N.  et al. Anti-neurofascin antibody in patients with combined central and peripheral demyelination. Neurology 81, 714\u2013722 (2013).","journal-title":"Neurology"},{"key":"BFnrneurol201784_CR62","doi-asserted-by":"publisher","first-page":"e238","DOI":"10.1212\/NXI.0000000000000238","volume":"3","author":"A Cortese","year":"2016","unstructured":"Cortese, A.  et al. Neurofascin-155 as a putative antigen in combined central and peripheral demyelination. Neurol. Neuroimmunol. Neuroinflamm. 3, e238 (2016).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"BFnrneurol201784_CR63","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jneuroim.2014.09.012","volume":"277","author":"W Yan","year":"2014","unstructured":"Yan, W.  et al. Antibodies to neurofascin exacerbate adoptive transfer experimental autoimmune neuritis. J. Neuroimmunol. 277, 13\u201317 (2014).","journal-title":"J. Neuroimmunol."},{"key":"BFnrneurol201784_CR64","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.nmd.2016.10.008","volume":"27","author":"J-M Vallat","year":"2016","unstructured":"Vallat, J.-M.  et al. Paranodal lesions in chronic inflammatory demyelinating polyneuropathy associated with anti-neurofascin 155 antibodies. Neuromuscul. Disord. 27, 290\u2013293 (2016).","journal-title":"Neuromuscul. Disord."},{"key":"BFnrneurol201784_CR65","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.neuron.2005.10.019","volume":"48","author":"DL Sherman","year":"2005","unstructured":"Sherman, D. L.  et al. Neurofascins are required to establish axonal domains for saltatory conduction. Neuron 48, 737\u2013742 (2005).","journal-title":"Neuron"},{"key":"BFnrneurol201784_CR66","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/nrn1701","volume":"6","author":"M Fitzgerald","year":"2005","unstructured":"Fitzgerald, M. The development of nociceptive circuits. Nat. Rev. Neurosci. 6, 507\u2013520 (2005).","journal-title":"Nat. Rev. Neurosci."},{"key":"BFnrneurol201784_CR67","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1091\/mbc.e06-06-0570","volume":"18","author":"C Bonnon","year":"2007","unstructured":"Bonnon, C.  et al. PGY repeats and N-glycans govern the trafficking of paranodin and its selective association with contactin and neurofascin-155. Mol. Biol. Cell 18, 229\u2013241 (2007).","journal-title":"Mol. Biol. Cell"},{"key":"BFnrneurol201784_CR68","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1093\/brain\/awg030","volume":"126","author":"MSG Kwa","year":"2003","unstructured":"Kwa, M. S. G. Autoimmunoreactivity to Schwann cells in patients with inflammatory neuropathies. Brain 126, 361\u2013375 (2003).","journal-title":"Brain"},{"key":"BFnrneurol201784_CR69","first-page":"202","volume":"21","author":"L Querol","year":"2016","unstructured":"Querol, L.  et al. Antibodies against peripheral nerve antigens in chronic inflammatory demyelinating polyradiculoneuropathy [poster abstract]. J. Peripher. Nerv. Syst. 21, 202\u2013203 (2016).","journal-title":"J. Peripher. Nerv. Syst."},{"key":"BFnrneurol201784_CR70","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1093\/brain\/awx124","volume":"140","author":"E Delmont","year":"2017","unstructured":"Delmont, E.  et al. Autoantibodies to nodal isoforms of neurofascin in chronic inflammatory demyelinating polyneuropathy. Brain 140, 1851\u20131858 (2017).","journal-title":"Brain"},{"key":"BFnrneurol201784_CR71","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa067752","volume":"357","author":"P Joly","year":"2007","unstructured":"Joly, P.  et al. A single cycle of rituximab for the treatment of severe pemphigus. N. Engl. J. Med. 357, 545\u2013552 (2007).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneurol201784_CR72","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1212\/WNL.0b013e3182407982","volume":"78","author":"J D\u00edaz-Manera","year":"2012","unstructured":"D\u00edaz-Manera, J.  et al. Long-lasting treatment effect of rituximab in MuSK myasthenia. Neurology 78, 189\u2013193 (2012).","journal-title":"Neurology"},{"key":"BFnrneurol201784_CR73","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1681\/ASN.2010111125","volume":"22","author":"LH Beck","year":"2011","unstructured":"Beck, L. H.  et al. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J. Am. Soc. Nephrol. 22, 1543\u20131550 (2011).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneurol201784_CR74","doi-asserted-by":"publisher","first-page":"e149","DOI":"10.1212\/NXI.0000000000000149","volume":"2","author":"L Querol","year":"2015","unstructured":"Querol, L.  et al. Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins. Neurol. Neuroimmunol. Neuroinflamm. 2, e149 (2015).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"BFnrneurol201784_CR75","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/277140a0","volume":"277","author":"M Kadlubowski","year":"1979","unstructured":"Kadlubowski, M. & Hughes, R. A. Identification of the neuritogen for experimental allergic neuritis. Nature 277, 140\u2013141 (1979).","journal-title":"Nature"},{"key":"BFnrneurol201784_CR76","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/S0165-5728(99)00269-6","volume":"104","author":"CM Gabriel","year":"2000","unstructured":"Gabriel, C. M., Gregson, N. A. & Hughes, R. A. Anti-PMP22 antibodies in patients with inflammatory neuropathy. J. Neuroimmunol. 104, 139\u2013146 (2000).","journal-title":"J. Neuroimmunol."},{"key":"BFnrneurol201784_CR77","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/ana.1129","volume":"50","author":"WX Yan","year":"2001","unstructured":"Yan, W. X., Archelos, J. J., Hartung, H.-P. & Pollard, J. D. P0 protein is a target antigen in chronic inflammatory demyelinating polyradiculoneuropathy. Ann. Neurol. 50, 286\u2013292 (2001).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol201784_CR78","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1136\/jnnp.2006.106617","volume":"78","author":"HR Inglis","year":"2007","unstructured":"Inglis, H. R., Csurhes, P. A. & McCombe, P. A. Antibody responses to peptides of peripheral nerve myelin proteins P0 and P2 in patients with inflammatory demyelinating neuropathy. J. Neurol. Neurosurg. Psychiatry 78, 419\u2013422 (2007).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BFnrneurol201784_CR79","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1002\/mus.20999","volume":"38","author":"R Rojas-Garcia","year":"2008","unstructured":"Rojas-Garcia, R., Gallardo, E., De La Torre, C., Sanvito, L. & Illa, I. Chronic sensorimotor polyradiculopathy with antibodies to P2: an electrophysiological and immunoproteomic analysis. Muscle Nerve 38, 933\u2013938 (2008).","journal-title":"Muscle Nerve"},{"key":"BFnrneurol201784_CR80","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/S0165-5728(01)00307-1","volume":"116","author":"MS Kwa","year":"2001","unstructured":"Kwa, M. S., van Schaik, I. N., Brand, A., Baas, F. & Vermeulen, M. Investigation of serum response to PMP22, connexin 32 and P(0) in inflammatory neuropathies. J. Neuroimmunol. 116, 220\u2013225 (2001).","journal-title":"J. Neuroimmunol."},{"key":"BFnrneurol201784_CR81","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S0165-5728(99)00250-7","volume":"104","author":"MF Ritz","year":"2000","unstructured":"Ritz, M. F.  et al. Characterisation of autoantibodies to peripheral myelin protein 22 in patients with hereditary and acquired neuropathies. J. Neuroimmunol. 104, 155\u2013163 (2000).","journal-title":"J. Neuroimmunol."},{"key":"BFnrneurol201784_CR82","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1093\/brain\/awf272","volume":"125","author":"HJ Willison","year":"2002","unstructured":"Willison, H. J. & Yuki, N. Peripheral neuropathies and anti-glycolipid antibodies. Brain 125, 2591\u20132625 (2002).","journal-title":"Brain"},{"key":"BFnrneurol201784_CR83","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jneuroim.2011.08.016","volume":"239","author":"M Kuwahara","year":"2011","unstructured":"Kuwahara, M., Suzuki, S., Takada, K. & Kusunoki, S. Antibodies to LM1 and LM1-containing ganglioside complexes in Guillain\u2013Barr\u00e9 syndrome and chronic inflammatory demyelinating polyneuropathy. J. Neuroimmunol. 239, 87\u201390 (2011).","journal-title":"J. Neuroimmunol."},{"key":"BFnrneurol201784_CR84","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1136\/jnnp-2012-303440","volume":"84","author":"M Kuwahara","year":"2013","unstructured":"Kuwahara, M.  et al. Clinical features of CIDP with LM1-associated antibodies. J. Neurol. Neurosurg. Psychiatry 84, 573\u2013575 (2013).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BFnrneurol201784_CR85","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1007\/s10875-014-0026-3","volume":"34","author":"O Harschnitz","year":"2014","unstructured":"Harschnitz, O.  et al. MMN: from immunological cross-talk to conduction block. J. Clin. Immunol. 34, 112\u2013119 (2014).","journal-title":"J. Clin. Immunol."},{"key":"BFnrneurol201784_CR86","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/mus.24326","volume":"51","author":"AB Sanderson","year":"2015","unstructured":"Sanderson, A. B., Arnold, W. D., Elsheikh, B. & Kissel, J. T. The clinical spectrum of isolated peripheral motor dysfunction. Muscle Nerve 51, 358\u2013362 (2015).","journal-title":"Muscle Nerve"},{"key":"BFnrneurol201784_CR87","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1212\/01.wnl.0000261163.44503.08","volume":"68","author":"DL Menkes","year":"2007","unstructured":"Menkes, D. L. Multifocal motor neuropathy with and without conduction block: a single entity? Neurology 68, 1161\u20131162 (2007).","journal-title":"Neurology"},{"key":"BFnrneurol201784_CR88","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1212\/01.wnl.0000234063.51897.20","volume":"67","author":"E Delmont","year":"2006","unstructured":"Delmont, E.  et al. Multifocal motor neuropathy with and without conduction block: a single entity? Neurology 67, 592\u2013596 (2006).","journal-title":"Neurology"},{"key":"BFnrneurol201784_CR89","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1136\/jnnp-2013-305755","volume":"85","author":"E Nobile-Orazio","year":"2014","unstructured":"Nobile-Orazio, E., Giannotta, C., Musset, L., Messina, P. & L\u00e9ger, J.-M. Sensitivity and predictive value of anti-GM1\/galactocerebroside IgM antibodies in multifocal motor neuropathy. J. Neurol. Neurosurg. Psychiatry 85, 754\u2013758 (2014).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BFnrneurol201784_CR90","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1136\/jnnp-2014-308118","volume":"86","author":"EA Cats","year":"2014","unstructured":"Cats, E. A.  et al. Clonality of anti-GM1 IgM antibodies in multifocal motor neuropathy and the Guillain\u2013Barr\u00e9 syndrome. J. Neurol. Neurosurg. Psychiatry 86, 502\u2013504 (2014).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BFnrneurol201784_CR91","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1002\/mus.880160606","volume":"16","author":"A Uncini","year":"1993","unstructured":"Uncini, A., Santoro, M., Corbo, M., Lugaresi, A. & Latov, N. Conduction abnormalities induced by sera of patients with multifocal motor neuropathy and anti-GM1 antibodies. Muscle Nerve 16, 610\u2013615 (1993).","journal-title":"Muscle Nerve"},{"key":"BFnrneurol201784_CR92","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1093\/brain\/122.5.807","volume":"122","author":"K Paparounas","year":"1999","unstructured":"Paparounas, K., O'Hanlon, G. M., O'Leary, C. P., Rowan, E. G. & Willison, H. J. Anti-ganglioside antibodies can bind peripheral nerve nodes of Ranvier and activate the complement cascade without inducing acute conduction block in vitro. Brain 122, 807\u2013816 (1999).","journal-title":"Brain"},{"key":"BFnrneurol201784_CR93","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.jneuroim.2009.11.012","volume":"219","author":"E Nobile-Orazio","year":"2010","unstructured":"Nobile-Orazio, E., Giannotta, C. & Briani, C. Anti-ganglioside complex IgM antibodies in multifocal motor neuropathy and chronic immune-mediated neuropathies. J. Neuroimmunol. 219, 119\u2013122 (2010).","journal-title":"J. Neuroimmunol."},{"key":"BFnrneurol201784_CR94","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jneuroim.2014.11.001","volume":"278","author":"E Delmont","year":"2015","unstructured":"Delmont, E.  et al. Improving the detection of IgM antibodies against glycolipids complexes of GM1 and galactocerebroside in multifocal motor neuropathy using glycoarray and ELISA assays. J. Neuroimmunol. 278, 159\u2013161 (2015).","journal-title":"J. Neuroimmunol."},{"key":"BFnrneurol201784_CR95","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/j.1468-1331.2006.01142.x","volume":"13","author":"N Strigl-Pill","year":"2006","unstructured":"Strigl-Pill, N.  et al. Prediction of response to IVIg treatment in patients with lower motor neurone disorders. Eur. J. Neurol. 13, 135\u2013140 (2006).","journal-title":"Eur. J. Neurol."},{"key":"BFnrneurol201784_CR96","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/ana.24680","volume":"80","author":"O Harschnitz","year":"2016","unstructured":"Harschnitz, O.  et al. Autoantibody pathogenicity in a multifocal motor neuropathy induced pluripotent stem cell-derived model. Ann. Neurol. 80, 71\u201388 (2016).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol201784_CR97","doi-asserted-by":"publisher","first-page":"e119","DOI":"10.1212\/NXI.0000000000000119","volume":"2","author":"L Vlam","year":"2015","unstructured":"Vlam, L.  et al. Complement activity is associated with disease severity in multifocal motor neuropathy. Neurol. Neuroimmunol. Neuroinflamm. 2, e119 (2015).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"BFnrneurol201784_CR98","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/j.1529-8027.2011.00328.x","volume":"16","author":"AM Fitzpatrick","year":"2011","unstructured":"Fitzpatrick, A. M.  et al. An open label clinical trial of complement inhibition in multifocal motor neuropathy. J. Peripher. Nerv. Syst. 16, 84\u201391 (2011).","journal-title":"J. Peripher. Nerv. Syst."},{"key":"BFnrneurol201784_CR99","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1002\/glia.20503","volume":"55","author":"K Susuki","year":"2007","unstructured":"Susuki, K.  et al. Gangliosides contribute to stability of paranodal junctions and ion channel clusters in myelinated nerve fibers. Glia 55, 746\u2013757 (2007).","journal-title":"Glia"},{"key":"BFnrneurol201784_CR100","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.jneuroim.2014.09.001","volume":"276","author":"F Notturno","year":"2014","unstructured":"Notturno, F.  et al. Autoantibodies to neurofascin-186 and gliomedin in multifocal motor neuropathy. J. Neuroimmunol. 276, 207\u2013212 (2014).","journal-title":"J. Neuroimmunol."},{"key":"BFnrneurol201784_CR101","doi-asserted-by":"publisher","first-page":"e0134274","DOI":"10.1371\/journal.pone.0134274","volume":"10","author":"K Doppler","year":"2015","unstructured":"Doppler, K.  et al. Contactin-1 and neurofascin-155\/-186 are not targets of auto-antibodies in multifocal motor neuropathy. PLoS ONE 10, e0134274 (2015).","journal-title":"PLoS ONE"},{"key":"BFnrneurol201784_CR102","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1212\/WNL.0b013e318296e92b","volume":"80","author":"JM Leger","year":"2013","unstructured":"Leger, J. M.  et al. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy. Neurology 80, 2217\u20132225 (2013).","journal-title":"Neurology"},{"key":"BFnrneurol201784_CR103","doi-asserted-by":"publisher","first-page":"450391","DOI":"10.1155\/2015\/450391","volume":"2015","author":"L Magy","year":"2015","unstructured":"Magy, L.  et al. Heterogeneity of polyneuropathy associated with anti-MAG antibodies. J. Immunol. Res. 2015, 450391 (2015).","journal-title":"J. Immunol. Res."},{"key":"BFnrneurol201784_CR104","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1111\/ene.12658","volume":"22","author":"C Giannotta","year":"2015","unstructured":"Giannotta, C., Di Pietro, D., Gallia, F. & Nobile-Orazio, E. Anti-sulfatide IgM antibodies in peripheral neuropathy: to test or not to test? Eur. J. Neurol. 22, 879\u2013882 (2015).","journal-title":"Eur. J. Neurol."},{"key":"BFnrneurol201784_CR105","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1212\/WNL.0b013e3181b59a80","volume":"73","author":"ML Kuijf","year":"2009","unstructured":"Kuijf, M. L.  et al. Detection of anti-MAG antibodies in polyneuropathy associated with IgM monoclonal gammopathy. Neurology 73, 688\u2013695 (2009).","journal-title":"Neurology"},{"key":"BFnrneurol201784_CR106","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.jns.2007.09.020","volume":"266","author":"E Nobile-Orazio","year":"2008","unstructured":"Nobile-Orazio, E.  et al. How useful are anti-neural IgM antibodies in the diagnosis of chronic immune-mediated neuropathies? J. Neurol. Sci. 266, 156\u2013163 (2008).","journal-title":"J. Neurol. Sci."},{"key":"BFnrneurol201784_CR107","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1212\/WNL.0b013e318296e92b","volume":"80","author":"JM L\u00e9ger","year":"2013","unstructured":"L\u00e9ger, J. M.  et al. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy. Neurology 80, 2217\u20132225 (2013).","journal-title":"Neurology"},{"key":"BFnrneurol201784_CR108","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/j.1529-8027.2007.00129.x","volume":"12","author":"L Benedetti","year":"2007","unstructured":"Benedetti, L.  et al. Predictors of response to rituximab in patients with neuropathy and anti-myelin associated glycoprotein immunoglobulin M. J. Peripher. Nerv. Syst. 12, 102\u2013107 (2007).","journal-title":"J. Peripher. Nerv. Syst."},{"key":"BFnrneurol201784_CR109","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1002\/mus.10359","volume":"27","author":"S Renaud","year":"2003","unstructured":"Renaud, S.  et al. Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies. Muscle Nerve 27, 611\u2013615 (2003).","journal-title":"Muscle Nerve"},{"key":"BFnrneurol201784_CR110","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/ana.21577","volume":"65","author":"MC Dalakas","year":"2009","unstructured":"Dalakas, M. C.  et al. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy. Ann. Neurol. 65, 286\u2013293 (2009).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol201784_CR111","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1212\/WNL.0000000000001044","volume":"83","author":"THP Draak","year":"2014","unstructured":"Draak, T. H. P.  et al. Changing outcome in inflammatory neuropathies: Rasch-comparative responsiveness. Neurology 83, 2124\u20132132 (2014).","journal-title":"Neurology"},{"key":"BFnrneurol201784_CR112","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1172\/JCI58743","volume":"122","author":"MA Maurer","year":"2012","unstructured":"Maurer, M. A.  et al. Rituximab induces sustained reduction of pathogenic B cells in patients with peripheral nervous system autoimmunity. J. Clin. Invest. 122, 1393\u20131402 (2012).","journal-title":"J. Clin. Invest."},{"key":"BFnrneurol201784_CR113","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1002\/(SICI)1097-4598(199908)22:8<1030::AID-MUS4>3.0.CO;2-H","volume":"22","author":"MF Ritz","year":"1999","unstructured":"Ritz, M. F.  et al. Anti-MAG IgM penetration into myelinated fibers correlates with the extent of myelin widening. Muscle Nerve 22, 1030\u20131037 (1999).","journal-title":"Muscle Nerve"},{"key":"BFnrneurol201784_CR114","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1002\/mus.880111111","volume":"11","author":"HJ Willison","year":"1988","unstructured":"Willison, H. J.  et al. Demyelination induced by intraneural injection of human antimyelin-associated glycoprotein antibodies. Muscle Nerve 11, 1169\u20131176 (1988).","journal-title":"Muscle Nerve"},{"key":"BFnrneurol201784_CR115","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jneuroim.2007.10.025","volume":"193","author":"AA Ilyas","year":"2008","unstructured":"Ilyas, A. A., Gu, Y., Dalakas, M. C., Quarles, R. H. & Bhatt, S. Induction of experimental ataxic sensory neuronopathy in cats by immunization with purified SGPG. J. Neuroimmunol. 193, 87\u201393 (2008).","journal-title":"J. Neuroimmunol."},{"key":"BFnrneurol201784_CR116","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1212\/WNL.37.2.242","volume":"37","author":"AP Hays","year":"1987","unstructured":"Hays, A. P., Latov, N., Takatsu, M. & Sherman, W. H. Experimental demyelination of nerve induced by serum of patients with neuropathy and an anti-MAG IgM M-protein. Neurology 37, 242\u2013256 (1987).","journal-title":"Neurology"},{"key":"BFnrneurol201784_CR117","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/ana.410330514","volume":"33","author":"AH Tatum","year":"1993","unstructured":"Tatum, A. H. Experimental paraprotein neuropathy, demyelination by passive transfer of human IgM anti-myelin-associated glycoprotein. Ann. Neurol. 33, 502\u2013506 (1993).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol201784_CR118","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1136\/jnnp.48.9.927","volume":"48","author":"AJ Steck","year":"1985","unstructured":"Steck, A. J.  et al. Passive transfer studies in demyelinating neuropathy with IgM monoclonal antibodies to myelin-associated glycoprotein. J. Neurol. Neurosurg. Psychiatry 48, 927\u2013929 (1985).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BFnrneurol201784_CR119","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1136\/jnnp.56.11.1178","volume":"56","author":"HJ Willison","year":"1993","unstructured":"Willison, H. J., Paterson, G., Veitch, J., Inglis, G. & Barnett, S. C. Peripheral neuropathy associated with monoclonal IgM anti-Pr2 cold agglutinins. J. Neurol. Neurosurg. Psychiatry 56, 1178\u20131183 (1993).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BFnrneurol201784_CR120","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S0165-5728(97)00130-6","volume":"80","author":"BC Jacobs","year":"1997","unstructured":"Jacobs, B. C.  et al. Human IgM paraproteins demonstrate shared reactivity between Campylobacter jejuni lipopolysaccharides and human peripheral nerve disialylated gangliosides. J. Neuroimmunol. 80, 23\u201330 (1997).","journal-title":"J. Neuroimmunol."},{"key":"BFnrneurol201784_CR121","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1136\/jnnp.2009.183517","volume":"81","author":"R Rojas-Garcia","year":"2010","unstructured":"Rojas-Garcia, R.  et al. Bulbar involvement in patients with antiganglioside antibodies against NeuNAc(\u03b12\u20133)Gal. J. Neurol. Neurosurg. Psychiatry 81, 623\u2013628 (2010).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BFnrneurol201784_CR122","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1056\/NEJMoa1200710","volume":"367","author":"SP Treon","year":"2012","unstructured":"Treon, S. P.  et al. MYD88 L265P somatic mutation in Waldenstr\u00f6m's macroglobulinemia. N. Engl. J. Med. 367, 826\u2013833 (2012).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneurol201784_CR123","doi-asserted-by":"publisher","first-page":"984","DOI":"10.3324\/haematol.2013.100552","volume":"99","author":"NW van de Donk","year":"2014","unstructured":"van de Donk, N. W.  et al. The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network. Haematologica 99, 984\u2013996 (2014).","journal-title":"Haematologica"},{"key":"BFnrneurol201784_CR124","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1055\/s-0034-1390391","volume":"34","author":"S Bhattacharyya","year":"2014","unstructured":"Bhattacharyya, S. & Helfgott, S. M. Neurologic complications of systemic lupus erythematosus, Sj\u00f6gren syndrome, and rheumatoid arthritis. Semin. Neurol. 34, 425\u2013436 (2014).","journal-title":"Semin. Neurol."},{"key":"BFnrneurol201784_CR125","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1136\/jnnp.2010.222109","volume":"82","author":"PP Pavlakis","year":"2011","unstructured":"Pavlakis, P. P.  et al. Peripheral neuropathies in Sj\u00f6gren syndrome: a new reappraisal. J. Neurol. Neurosurg. Psychiatry 82, 798\u2013802 (2011).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BFnrneurol201784_CR126","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S1474-4422(13)70236-9","volume":"13","author":"KG Gwathmey","year":"2014","unstructured":"Gwathmey, K. G., Burns, T. M., Collins, M. P. & Dyck, P. J. B. Vasculitic neuropathies. Lancet Neurol. 13, 67\u201382 (2014).","journal-title":"Lancet Neurol."},{"key":"BFnrneurol201784_CR127","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.autrev.2013.09.002","volume":"13","author":"E Kaltsonoudis","year":"2014","unstructured":"Kaltsonoudis, E., Voulgari, P. V., Konitsiotis, S. & Drosos, A. A. Demyelination and other neurological adverse events after anti-TNF therapy. Autoimmun. Rev. 13, 54\u201358 (2014).","journal-title":"Autoimmun. Rev."},{"key":"BFnrneurol201784_CR128","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/mus.20924","volume":"37","author":"J-P St\u00fcbgen","year":"2008","unstructured":"St\u00fcbgen, J.-P. Tumor necrosis factor-\u03b1 antagonists and neuropathy. Muscle Nerve 37, 281\u2013292 (2008).","journal-title":"Muscle Nerve"},{"key":"BFnrneurol201784_CR129","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1002\/mus.24969","volume":"53","author":"K Farhad","year":"2016","unstructured":"Farhad, K., Traub, R., Ruzhansky, K. M. & Brannagan, T. H. III. Causes of neuropathy in patients referred as 'idiopathic neuropathy'. Muscle Nerve 53, 856\u2013861 (2016).","journal-title":"Muscle Nerve"},{"key":"BFnrneurol201784_CR130","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1136\/jnnp-2014-309730","volume":"86","author":"J-C Antoine","year":"2015","unstructured":"Antoine, J.-C.  et al. Antifibroblast growth factor receptor 3 antibodies identify a subgroup of patients with sensory neuropathy. J. Neurol. Neurosurg. Psychiatry 86, 1347\u20131355 (2015).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BFnrneurol201784_CR131","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1468-1331.2010.03220.x","volume":"18","author":"MJ Titulaer","year":"2011","unstructured":"Titulaer, M. J.  et al. Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur. J. Neurol. 18, 19\u201327 (2011).","journal-title":"Eur. J. Neurol."},{"key":"BFnrneurol201784_CR132","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s00415-009-5431-9","volume":"257","author":"F Graus","year":"2010","unstructured":"Graus, F., Saiz, A. & Dalmau, J. Antibodies and neuronal autoimmune disorders of the CNS. J. Neurol. 257, 509\u2013517 (2010).","journal-title":"J. Neurol."},{"key":"BFnrneurol201784_CR133","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/CND.0b013e3182a04538","volume":"15","author":"Y Hannawi","year":"2013","unstructured":"Hannawi, Y.  et al. A case of severe chronic progressive axonal polyradiculoneuropathy temporally associated with anti-CV2\/CRMP5 antibodies. J. Clin. Neuromuscul. Dis. 15, 13\u201318 (2013).","journal-title":"J. Clin. Neuromuscul. Dis."},{"key":"BFnrneurol201784_CR134","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1002\/1531-8249(20010201)49:2<214::AID-ANA41>3.0.CO;2-W","volume":"49","author":"JC Antoine","year":"2001","unstructured":"Antoine, J. C.  et al. Paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy. Ann. Neurol. 49, 214\u2013221 (2001).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol201784_CR135","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1002\/ana.22297","volume":"69","author":"E Lancaster","year":"2011","unstructured":"Lancaster, E.  et al. Investigations of Caspr2, an autoantigen of encephalitis and neuromyotonia. Ann. Neurol. 69, 303\u2013311 (2011).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol201784_CR136","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1212\/WNL.0000000000002917","volume":"87","author":"A van Sonderen","year":"2016","unstructured":"van Sonderen, A.  et al. The clinical spectrum of Caspr2 antibody-associated disease. Neurology 87, 521\u2013528 (2016).","journal-title":"Neurology"},{"key":"BFnrneurol201784_CR137","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1212\/WNL.0000000000003293","volume":"87","author":"R Hanewinckel","year":"2016","unstructured":"Hanewinckel, R.  et al. Prevalence of polyneuropathy in the general middle-aged and elderly population. Neurology 87, 1892\u20131898 (2016).","journal-title":"Neurology"},{"key":"BFnrneurol201784_CR138","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","volume":"15","author":"F Graus","year":"2016","unstructured":"Graus, F.  et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 15, 391\u2013404 (2016).","journal-title":"Lancet Neurol."},{"key":"BFnrneurol201784_CR139","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.jaci.2013.01.014","volume":"131","author":"W van de Veen","year":"2013","unstructured":"van de Veen, W.  et al. IgG4 production is confined to human IL-10-producing regulatory B cells that suppress antigen-specific immune responses. J. Allergy Clin. Immunol. 131, 1204\u20131212 (2013).","journal-title":"J. Allergy Clin. Immunol."},{"key":"BFnrneurol201784_CR140","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1126\/science.1144603","volume":"317","author":"M van der Neut Kolfschoten","year":"2007","unstructured":"van der Neut Kolfschoten, M.  et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 317, 1554\u20131557 (2007).","journal-title":"Science"},{"key":"BFnrneurol201784_CR141","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/j.1365-2222.2009.03207.x","volume":"39","author":"RC Aalberse","year":"2009","unstructured":"Aalberse, R. C., Stapel, S. O., Schuurman, J. & Rispens, T. Immunoglobulin G4: an odd antibody. Clin. Exp. Allergy 39, 469\u2013477 (2009).","journal-title":"Clin. Exp. Allergy"},{"key":"BFnrneurol201784_CR142","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3389\/fimmu.2013.00235","volume":"4","author":"AM Collins","year":"2013","unstructured":"Collins, A. M. & Jackson, K. J. A temporal model of human IgE and IgG antibody function. Front. Immunol. 4, 235 (2013).","journal-title":"Front. Immunol."},{"key":"BFnrneurol201784_CR143","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jneuroim.2015.12.016","volume":"291","author":"MG Huijbers","year":"2016","unstructured":"Huijbers, M. G.  et al. Longitudinal epitope mapping in MuSK myasthenia gravis: implications for disease severity. J. Neuroimmunol. 291, 82\u201388 (2016).","journal-title":"J. Neuroimmunol."},{"key":"BFnrneurol201784_CR144","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.jaci.2016.07.006","volume":"138","author":"W van de Veen","year":"2016","unstructured":"van de Veen, W.  et al. Role of regulatory B cells in immune tolerance to allergens and beyond. J. Allergy Clin. Immunol. 138, 654\u2013665 (2016).","journal-title":"J. Allergy Clin. Immunol."},{"key":"BFnrneurol201784_CR145","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.1172\/JCI64413","volume":"122","author":"G Di Zenzo","year":"2012","unstructured":"Di Zenzo, G.  et al. Pemphigus autoantibodies generated through somatic mutations target the desmoglein-3 cis-interface. J. Clin. Invest. 122, 3781\u20133790 (2012).","journal-title":"J. Clin. Invest."},{"key":"BFnrneurol201784_CR146","doi-asserted-by":"publisher","first-page":"20783","DOI":"10.1073\/pnas.1313944110","volume":"110","author":"MG Huijbers","year":"2013","unstructured":"Huijbers, M. G.  et al. MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4. Proc. Natl Acad. Sci. USA 110, 20783\u201320788 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneurol201784_CR147","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/nrneurol.2014.253","volume":"11","author":"JD L\u00fcnemann","year":"2015","unstructured":"L\u00fcnemann, J. D., Nimmerjahn, F. & Dalakas, M. C. Intravenous immunoglobulin in neurology \u2014 mode of action and clinical efficacy. Nat. Rev. Neurol. 11, 80\u201389 (2015).","journal-title":"Nat. Rev. Neurol."}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrneurol.2017.84.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneurol.2017.84","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/nrneurol.2017.84","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/nrneurol.2017.84.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:22:31Z","timestamp":1684470151000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrneurol.2017.84"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,14]]},"references-count":147,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["BFnrneurol201784"],"URL":"https:\/\/doi.org\/10.1038\/nrneurol.2017.84","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,14]]},"assertion":[{"value":"14 July 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}